Advertise on podcast: Ask Stago (english version)

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in coagulation.  In today’s episode, our guest Doctor Isabelle Gouin-Thibault will discuss the influence of dextran sulfate in anti-Xa assay.  Literature sources:  Lasne, D. et al. (2023) Factors Influencing Anti-Xa Assays: A Multicenter Prospective Study in Critically Ill and Noncritically Ill Patients Receiving Unfractionated Heparin. Thrombosis and Haemostasis, 123 (12), 1105. Hardy, M. et al. (2023) Reassessment of dextran sulfate in anti-Xa assay for unfractionated heparin laboratory monitoring. Res Pract Thromb Haemost. 7 (8), 102257     Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice. 

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In this “back to basics” mini-series, Dr LaShanta Brice will discuss the clinical utility of the three most common parameters tested in the lab, the PT, APTT and Fibrinogen. Today we are going to cover the Prothrombin Time! We will discover why an order for a PT would be received by the lab, generally why the PT is used in practice and some emerging trends particularly when considering the INR clinic. Happy listening! Literature source: CLSI H47 One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test     Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today’s episode, Emily Pullen, North America Product Manager, will tell us more about Stago solution to improve lab productivity with the STA Workcell Max. Literature sources: https://www.stago.com/products-services/max-generation-analysers/sta-workcell-max/76f0f5a022edbacbce5ceea5f072e0c4  Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today’s episode, our guest Dr. Refaai  will help us understand the formation and function of fibrin monomers (FM) in hemostasis, highlighting their crucial role in coagulation and clot formation and the need for more prospective studies to validate this assay for clinical indications such as DIC, VTE and cancer. Literature sources: Refaai M.A. (2018) The Clinical Significance of Fibrin Monomers. Thromb Haemost, 118, 1856.Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation.  In today’s episode, Anne-Cécile Ortega will further explain what a MyOptiLab audit is — a service offered by Stago that involves a comprehensive workflow study using the Lean Six Sigma methodology. This audit is designed to help laboratories enhance their efficiency by identifying areas for improvement and optimizing processes.  Literature sources: Bhat, R., & Wagh, P. (2013). "Application of Six Sigma methodology in clinical diagnostic laboratories: A case study."  International Journal of Scientific and Research Publications*, 3(7), 1-6.  Goh, T. N., & Ang, K. S. (2011). "The application of Lean Six Sigma in healthcare."  International Journal of Quality & Reliability Management*, 28(6), 548-564.  Sundararajan, V., & Sharma, P. (2012). "Lean Six Sigma in the clinical laboratory: Achieving improvement in laboratory processes."  Clinical Laboratory Management Review*, 26(2), 82-89.  Kendall, J., & Jones, D. (2017). "The role of Lean Six Sigma in clinical laboratory testing." American Journal of Clinical Pathology*, 147(3), 298-305.  Sofiya, L., & Mirza, M. (2014). "Enhancing diagnostic laboratory performance through Lean Six Sigma." Journal of Healthcare Engineering*, 2014, Article ID 870376, 10 pages.    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today’s episode, Karine Carrière  will explain further what are microvesicles, their importance in coagulation and how to analyze them.  Literature sources: [Tesselaar et al.], [Lacroix et al.] [Faille et al.] [Mullier et al.] Vallier et al.] . [Nieuwland et al.]Kim HK, Song KS, Park YS, Kang YH, Lw YJ, Lw KR, et al.Elevated levels of circulating platelet microparticles, VEGF, 11-6 andFiANTES in patients Wlth gastrlc cancer. possible mle of a metastasispredlotor. Eur J Cancer 2003;39(2):184-91.Helley D, Banu E, Bouziane A, Banu A, Scotte F, Fiher AM, et al. Platelet microparticles: a potential predictive factor of survival in hormone-reac pmstate cancer patients treated with docetaxel-based chemotherapy. Eur Urnl2009;56(3):479-84.Zwicker JI, Liebman HA, Neuberg D, Lecmix R, Bauer KA, Furie BC, et ai. Tmr-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15 (22): 68630-40  Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. This month we meet Joseph Bautista, is a 37 year old US man living with a rare clotting disorder, a Factor XI deficiency otherwise known as Hemophilia C. His journey so far has not been an easy one but by educating himself and advocating for the best care he is living a full and healthy life working as a data architect in the IT sector. Its an inspiring and reassuring story for anyone facing a rare bleeding disorder diagnosis & proves the importance of patient empowerment.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today’s episode, our guest Evelyne Escarmant will help us to understand what is behind the recent update of ISO 15189 and what it means for us as manufacturers and indeed the clinical laboratory Literature sources:  ISO 15189; Medical laboratories – Requirements for quality and competence  Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today’s episode, our guest Florence Crépet will help us to understand what is behind the wording “limit of blank”, “limit of detection” and “limit of quantification”, and what it means for the clinical laboratory Literature sources: Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008 Aug;29 Suppl 1(Suppl 1):S49-52.CLSI. Evaluation of Detection Capability for Clinical Laboratory Measurement  Procedures; Approved  Guideline—Second  Edition. CLSI  document EP17-A2. Wayne,  PA: Clinical and Laboratory  Standards Institute; 2012.CLSI Evaluation of Detection Capability Implementation Guide. CLSI Document EP17-Ed2-IG. Wayne, PA: Clinical and Laboratory Standards Institute; 2021.  Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In this episode, to coincide with International Womens Day (March 8th), we are focusing on Gender equality in the workforce, why this is good for business and good for society overall. We meet with Eva Ohlsson Desormonts, Group HR Director for Stago and Amandine Serret International Business Support and Communications Director for Stago as well as an Executive Coach. Literature sources: Women in the Workpace 2022, McKinsey & Company whitepaperChallenges facing early career women in thrombosis and hemostasis—meeting the needs of the next generation, Guest Editorial, J Thromb Haemost. 2022;20:2453-5455  Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today’s episode, we are delighted to speak to April Matera. April experienced a stroke at the age of 39 and from there began her journey towards an anti-phospholipid syndrome diagnosis. Unfortunately it took 7 different visits to 7 different doctors to get her there. She tells us here about her APS road and how it has impacted her life and her dream to have a family.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In this series of our new season we will be covering Womens’ health and looking at the broader implications of coagulation and then speaking to a Lupus patient advocate on the impact this disease has had for her personally. To start off, in today episode, we are delighted to speak to our Clinical Development Director, Dr Francois Depasse about the broader connection between Womens’ Health and coagulation and then a more in depth look at APS. Links to related podcasts: S1E13 - Lupus anticoagulant diagnosis work-up https://www.podcastics.com/podcast/episode/13-the-lupus-anticoagulant-diagnosis-work-up-54015/ S3E7 - Hemostasis results interpretation along pregnancy https://www.podcastics.com/podcast/episode/s3e7-hemostasis-results-interpretation-along-pregnancy-134753/ Literature sources: https://www.cdc.gov/ncbddd/blooddisorders/women/facts.html Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306Devreese KMJ, Ortel TL, Pengo V, de Laat B; Subcommittee on Lupus anticoagulant/Antiphospholipid antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16: 809-813CLSI Laboratory testing for the Lupus anticoagulant - Approved Guideline. CLSI document H60-A. Wayne, PA; 2014.Devreese, KMJ, de Groot, PG, de Laat, B, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020; 18: 2828– 2839. https://doi.org/10.1111/jth.15047   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today’s episode, our guest Professor Romaric Lacroix will explain us how fibrinolysis is important to the whole hemostasis process and how the sample fibrinolytic activity needs to be evaluated and sometimes monitored. Link to previous podcasts: S1E15 – Disseminated Intravascular Coagulation (DIC) and fibrin related markershttps://www.podcastics.com/podcast/episode/15-disseminated-intravascular-coagulation-dic-and-fibrin-related-markers-54016/  Literature sources: Cointe S, Vallier L, Esnault P, Dacos M, Bonifay A, Macagno N, Harti Souab K, Chareyre C, Judicone C, Frankel D, Robert S, Hraiech S, Alessi MC, Poncelet P, Albanese J, Dignat-George F, Lacroix R. Granulocyte microvesicles with a high plasmin generation capacity promote clot lysis and improve outcome in septic shock. Blood. 2022 Apr 14;139(15):2377-2391.Cointe S, Harti Souab K, Bouriche T, Vallier L, Bonifay A, Judicone C, Robert S, Armand R, Poncelet P, Albanese J, Dignat-George F et Lacroix R. A new assay to evaluate microvesicle plasmin generation capacity: validation in disease with fibrinolysis imbalance. J Extracell Vesicles 2018; Jul 16;7(1):1494482Vallier L, Cointe S, Lacroix R, Bonnifay A, Judicone C, Dignat-George F, Hau C.Kwaan. Microparticle and fibrinolysis. Semin Thromb Hemost. 2017 Mar;43(2):129-134  Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today’s episode, our guest Tom Childs will help us to understand the goal and clinical benefits of the Factor parallelism method.   Link to previous podcasts: S1E11 – How to be more productive (part 1): implementation of a rules enginehttps://www.podcastics.com/podcast/episode/10-how-to-be-more-productive-part-1-implementation-of-a-rules-engine-37749/  S2E8 - World Hemophilia Dayhttps://www.podcastics.com/podcast/episode/s2e8-world-hemophilia-day-72341/  S2E4 - How to determine factor levels in hemophilia?https://www.podcastics.com/podcast/episode/s2e4-how-to-determine-factor-levels-in-hemophilia-62593/  Literature sources: Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program 2006: 432–7 (https://ashpublications.org/hematology/article/2006/1/432/19703/Acquired-Factor-VIII-Inhibitors-Pathophysiology).Morfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008; 14 (Suppl 6): 20–2.Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (7): 2358–63Monahan PE, Baker JR, Riske B, Soucie JM. Physical functioning in boys with hemophilia in the U.S. Am J Prev Med 2011; 41 (6 Suppl 4): S360–8.Collins PW, Chalmers E, Hart D et al.; United Kingdom Haemophilia Centre Doctors’ Organization. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol 2013; 162 (6): 758–73 (https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.12463).Riley PW, Gallea B, Valcour A. Development and implementation of a coagulation factor testing method utilizing autoverification in a high‑volume clinical reference laboratory environment. J Pathol Inform 2017; 8: 25.Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4 (1): 59–72Oldenburg J, Mahlangu JN, Kim B et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (9): 809–18.Florin L, Desloovere M, Devreese KML. Validation of an automated algorithm for interpretation of lupus anticoagulant testing on the Stago STA R Max (Poster). International Society on Thrombosis and Haemostasis, 2017.  Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today’s episode, our guest Gabrielle Pearl will explain us the particularities of thrombosis and hemostasis in pediatric population, and how to manage pediatric patient samples in the clinical laboratory. Link to previous podcasts: S2E5 - How to collect and prepare the coagulation samples properly?https://www.podcastics.com/podcast/episode/s2e5-how-to-collect-and-prepare-the-coagulation-samples-properly-67393/ S2E3 - How to establish and control the reference range of my assay?https://www.podcastics.com/podcast/episode/s2e3-how-to-establish-and-control-the-reference-range-of-my-assay-60155/   Literature sources: Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, De Rosa L, Hamilton S, Ragg P, Robinson S, Auldist A, Crock C, Roy N, Rowlands S. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006 Feb;95(2):362-72. doi: 10.1160/TH05-01-0047.Monagle P, Massicotte P. Developmental haemostasis: secondary haemostasis. Semin Fetal Neonatal Med. 2011 Dec;16(6):294-300. doi: 10.1016/j.siny.2011.07.007.Attard C, van der Straaten T, Karlaftis V, Monagle P, Ignjatovic V. Developmental hemostasis: age-specific differences in the levels of hemostatic proteins. J Thromb Haemost 2013; 11: 1850–4.Flanders MM, Phansalkar AR, Crist RA, Roberts WL, Rodgers GM. Pediatric reference intervals for uncommon bleeding and thrombotic disorders. J Pediatr. 2006 Aug;149(2):275-7. doi: 10.1016/j.jpeds.2006.04.008Lippi G, Franchini M, Montagnana M, Guidi GC. Coagulation testing in pediatric patients: the young are not just miniature adults. Semin Thromb Hemost. 2007 Nov;33(8):816-20. doi: 10.1055/s-2007-1000373.  Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice